30 closest matches · ranked by relevance
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
Childhood Brain Tumors
Primary: Number of Participants With Objective Response — 1; 5; 6; 18 Participants
Diffuse Intrinsic Pontine Glioma
Primary: Two Year Survival of Pediatric Patients With Diffuse Pontine Gliomas — 14.29 Percentage of patients
Glial Cell Tumors · Malignant Gliomas · Glioblastoma Multiforme
Primary: 1-year Event Free Survival (EFS) — 12; 24 percentage of participants — p=< 0.05
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Brain Tumor · Low Grade Glioma · Astrocytoma
Primary: Endocrine Dysfunction — 14.5; 20.2 percentage of participants
Brain Tumors
Primary: Progression Free Survival — 70 percentage of no progression
Visual Pathway Glioma
Primary: Number of Participants With Objective Response — 2; 2; 3; 1 Participants
Central Nervous System Tumors
Primary: Measurement of Number of Adverse Events — 4; 6; 3; 5 Adverse events
Brain Stem Gliomas
Primary: Number of Participants With Objective Response — 5; 4; 8; 14 Participants
Anaplastic Astrocytoma · Central Nervous System Neoplasm · Glioblastoma
Primary: One Year Overall Survival — 0.7208 Estimated probability
Brain Tumor · Central Nervous System Tumor
Primary: Marginal-failure Rate — 0 percentage of failure rate
Low-grade Glioma
Primary: Progression-free Survival — 23.1 percentage
Pediatric Recurrent Progressive Low-grade Gliomas · Pediatric Progressive Low-grade Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months — 67 percentage
Childhood CNS Primitive Neuroectodermal Tumor
Primary: Number of Participants With Objective Response — 3; 1; 1; 7 Participants
High Grade Glioma
Primary: Event-Free Survival (EFS) as Assessed by the Central Radiology Review Committee (CRRC) — 11.79; 8.21 months — p=0.1292
Medulloblastoma · Neuroectodermal Tumor
Primary: 12 Month Progression-free Survival (PFS-12) — 215; 69 Days — p=0.927
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
Low Grade Astrocytomas
Primary: Number of Participants With Objective Response — 4; 1; 4; 0 Participants
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants
Brain Tumors
Primary: Event-free Survival (EFS)
Brain Tumor · Central Nervous System Tumor
Primary: Short Term Feasibility Success — 25 participants
Brain Neoplasms
Primary: [18F] Fluorothymidine ([18F]-FLT) Uptake as a Marker of Cellular Proliferation — 1.57; 3.00 SUV max — p=< 0.001
Central Nervous System Tumors · Brain Tumors
Primary: Local Tumor Control — 0.966; 0.959; 1.000; 1.000 Proportion of patients
Glioma · Medulloblastoma
Primary: Percentage of Participants With Objective Response of Complete Response or Partial Response — 32.6; 0 percentage of participants
Brain and Central Nervous System Tumors
Primary: Percentage of Participants With an Objective Response (Complete Response or Partial Response) — 4; 0 Percent of Participants
Central Nervous System Nongerminomatous Germ Cell Tumor · Childhood Germinoma
Primary: 3-year Progression-free Survival (PFS) Rate of Patients With Nongerminomatous Germ Cell Tumor (NGGCT) Who Were Treated With Reduced Dose Whole Ventricular-field…
Malignant Glioma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma
Primary: Percentage of Participants With Unacceptable Toxicity — 0 percentage of participants
Central Nervous System Neoplasm · Pineoblastoma · Recurrent Medulloblastoma
Primary: Overall Survival — 2.43; 13.6 percent probability
Anaplastic Medulloblastoma · Medulloblastoma · Supratentorial Embryonal Tumor, Not Otherwise Specified
Primary: Number of Patients Who Have Either a Complete Response (CR) Rate or No Complete Response Rate — 13; 15; 16; 15 Participants — p=0.35